Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
European Innovation Council
BioCentury | Feb 6, 2025
Finance
European start-ups Akribion, Aplagon each draw funding: Venture Report
German biotech Akribion advancing nucleases for programmable cell depletion; Finland’s Aplagon developing vascular treatment
BioCentury | Jun 21, 2024
Finance
Venture Report: Syncona’s backs a pair of biotechs; Marea makes debut with $190M
Plus: Forbion’s new sustainability fund, and rounds for Elion, ashibio, NephroDI and Ability
BioCentury | Dec 13, 2023
Finance
Dec. 12 Quick Takes: Targeted genomic DNA insertion company Tome launches with $213M
Plus: Bicara’s latest big round is a $165M series C, Shinobi launches, Pfizer readies to close Seagen deal and more
BioCentury | Oct 11, 2023
Deals
Oct. 10 Quick Takes: Sanofi strikes another AI partnership via BioMap biologics design deal
Plus: With restructuring, Sana to focus on
BioCentury | Jun 27, 2023
Product Development
June 27 Quick Takes: FDA denies Regeneron’s high-dose Eylea
Plus: Sanofi meets in atopic dermatitis and updates from Nkarta, Astraveus and more
BioCentury | May 26, 2023
Finance
May 25 Quick Takes: VarmX is latest biotech to extend series B
Plus: Apellis/Sobi candidate misses in ALS and updates from Annexon, Pfizer and more
BioCentury | May 25, 2023
Management Tracks
Alvin Luk named CEO of HuidaGene
Plus:TScan’s MacBeath now permanent CEO; chair, CMO, seed money for InProTher
BioCentury | May 4, 2023
Finance
May 3 Quick Takes: Clinical-stage targeted radio-antibody newco Convergent raises $90M A round
Plus: Big gain for ImmunoGen as Elahere hits mark in confirmatory study and updates from Cowen, Longwood, Morphic, Arthex and Dianthus
BioCentury | Oct 21, 2022
Politics, Policy & Law
Oct. 20 Quick Takes: Novartis commits first cancer therapy to UN patent pool
Plus: AbbVie gains LPAR1 antibody via $255M buy of DJS and updates for Denali, the U.K., Kite-Refuge, Takeda-Zedira, Immunic, Talaris, Celeris
BioCentury | Jun 25, 2022
Regulation
June 24 Quick Takes: Innovent, Lilly gain China label expansion in gastric cancer
Plus GSK, Sanofi report COVID-19 booster vaccine efficacy, and updates from Cytokinetics, Novartis, Idoven and more
Items per page:
1 - 10 of 13